Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2013 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00867269
First received: March 20, 2009
Last updated: June 5, 2014
Last verified: October 2013

March 20, 2009
June 5, 2014
March 2009
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00867269 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

Background:

  • Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased level of CD4+ lymphocytes (a type of white blood cell), which can lead to opportunistic infections or autoimmune disorders and diseases.

Objectives:

  • To characterize the natural history with regard to CD4+ T cell count and onset of infection, malignancy, and autoimmunity.
  • To describe the immunological status of patients affected by ICL while providing the best possible standard therapy to eradicate opportunistic infections.
  • To establish the timeline of CD4 lymphocytopenia, with particular focus on defining subgroups of patients according to the decline, stabilization, or rise of CD4+ T cell counts over time.
  • To characterize the opportunistic infections that occur in ICL patients at microbiologic and molecular levels.
  • To characterize the immunophenotype and possible genetic immunodeficiency causes of ICL.
  • To determine whether measurable immunologic parameters correlate with the development of opportunistic infections or other comorbidities such as lymphoma in patients with ICL.
  • To determine whether there is any association between ICL and autoimmunity.
  • To determine CD4+ T cell turnover, survival, functionality, and cytokine responsiveness in ICL patients.

Eligibility:

  • Patients 2 years of age and older with an absolute CD4 count less than 300 in children 6 years or older and adults or less than 20% of T cells in children younger than 6 on two occasions at least 6 weeks apart.
  • Patients with negative results of HIV testing by ELISA, Western Blot, and viral load.
  • Patients must not have underlying immunodeficiency conditions, be receiving cytotoxic chemotherapy (anti-cancer drugs that kill cells), or have cancer.

Design:

  • At the initial visit to the National Institutes of Health, the following evaluations will be conducted:
  • Personal and family medical histories.
  • Physical examination, including rheumatology evaluation and other consultations as medically indicated (e.g., dermatology, pulmonology, ophthalmology, imaging studies).
  • Blood samples for analysis of red and white blood cell counts, liver function, immune hormones, and antibody and autoantibody levels, white blood cell growth and function, and DNA.
  • Urinalysis and urine pregnancy testing for female patients of childbearing age.
  • Evaluation and treatment of active infections as medically indicated, including biopsies, buccal swabs, pulmonary function tests, and imaging studies.
  • Follow-up visits will take place approximately every 12 months or more frequently if indicated, and will continue for a minimum of 4 years and a maximum of 10 years.
  • Evaluations at follow-up will include blood samples (i.e., CBC with differential, biochemical profile, HIV testing, etc.) and urinalysis and rheumatology consults.

Idiopathic CD4+ lymphocytopenia (ICL) is a disorder characterized by decreased numbers of circulating CD4+ T lymphocytes in the absence of known causes of CD4+ lymphocytopenia. ICL is defined as an absolute CD4+ T cell count of less than 300 cells/mL in a patient with no human immunodeficiency virus infection or known immunodeficiency syndrome. The causes and frequency of the disorder remain unknown. The condition is typically diagnosed when patients present with a serious infection. In this natural history protocol, we will evaluate patients with CD4+ T cell counts below 300 cells/microL. We propose to follow 200 patients for a minimum of 4 and maximum of 14 years, with a particular focus on the association between ICL and autoimmune disease. We will collect blood for immunologic, rheumatologic, and genetic testing in an effort to identify and understand the underlying defects that cause ICL and follow its course in a cohort of patients who will receive best standard therapy for opportunistic infections.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Idiopathic CD4+ Lymphocytopenia
  • Cryptococcal Meningitis
  • Warts
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
Not Provided
Not Provided
  • INCLUSION CRITERIA:

To be eligible for this study, patients must satisfy all of the following inclusion criteria:

  • Age greater than or equal to 18 years
  • Absolute CD4 count < 300 cells/microL or < 20% of total T cells on at least two occasions at least 6 weeks apart
  • Ongoing care by a referring primary care physician
  • Willingness to allow storage of blood and tissue samples for future analysis

EXCLUSION CRITERIA:

Patients will be ineligible for this study if they satisfy any of the following criteria:

  • Known infection with HIV-1, HIV-2, or human T-cell lymphotropic viruses (HTLV-1 or HTLV-2) as demonstrated by ELISA and Western blot and/or viral load testing
  • Known underlying immunodeficiency syndrome other than ICL
  • Evidence of active malignancy
  • Receipt of medications, herbal substances, or biologic agents known to diminish the CD4+ count within 30 days of when the CD4+ lymphocytopenia was detected
  • Any condition that in the judgment of the investigators would place the subject at undue risk or compromise the results of the study.
Both
18 Years and older
No
Contact: Gregg A Roby, R.N. (301) 435-8008
Contact: Virginia M Sheikh, M.D. (301) 435-7939 sheikhv@niaid.nih.gov
United States
 
NCT00867269
090102, 09-I-0102
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Principal Investigator: Virginia M Sheikh, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health Clinical Center (CC)
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP